SAN DIEGO, Aug. 30, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences,
will be presenting at the Baird 2017 Global Healthcare Conference
in New York City.
The live presentation takes place on Wednesday, September 6 at 2:35pm ET (11:35am
PT). The presentation will be webcast and may be
accessed on the Company's website at
http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. The Company
markets INGREZZA® (valbenazine) in the United States for
the treatment of adults with tardive dyskinesia. INGREZZA is a
novel, selective vesicular monoamine transporter 2 (VMAT2)
inhibitor, and is the first and only FDA-approved product indicated
for the treatment of adults with tardive dyskinesia. The
Company's three late-stage clinical programs are: elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc.; opicapone, a novel, once-daily,
peripherally-acting, highly-selective catechol-o-methyltransferase
inhibitor under investigation as adjunct therapy to levodopa in
Parkinson's patients; and INGREZZA, a novel, once-daily, selective
VMAT2 inhibitor under investigation for the treatment of Tourette
syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-baird-2017-global-healthcare-conference-300511015.html
SOURCE Neurocrine Biosciences, Inc.